. Author manuscript; available in PMC: 2015 Jan 1.

Published in final edited form as: J Pediatr. 2013 Aug 27;164(1):34–39.e2. doi: 10.1016/j.jpeds.2013.07.027

Table 3. Mortality and neurodevelopmental findings at 18 to 22 months according to treatment assignment (adjusted analysis).

Variable	Dexamethasone	Placebo	RR (95% CI)	P-value
	No. / total No. (%)
Primary outcome
Death or NDI	66/102(65)	61/92(66)	1.00(0.83,1.21)	0.99
Specific outcomes in survivors
Moderate to severe cerebral palsy	6/76(8)	8/68(12)	0.68(0.25,1.81)	0.43
Bilateral blindness	1/76(1.3)	0/67(0)	-	-
Deafness^*	2/75(2.7)	2/67(3.0)	0.82(0.10,6.86)	0.86
Bayley MDI <70^*	35/76(46)	25/62(40)	1.11(0.76,1.62)	0.60
Bayley PDI <70	21/74(28)	22/62(35)	0.79(0.49,1.28)	0.34
NDI	40/76(53)	31/62(50)	0.99(0.72,1.36)	0.97
Abnormal neurologic exam^*	20/76(26)	17/68(25)	1.02(0.59,1.78)	0.94

NDI = Neurodevelopmental impairment (moderate/severe cerebral palsy, MDI or PDI less than 70, blindness or hearing impairment). MDI = Mental developmental index; PDI = Psychomotor developmental index; RR is the relative risk of the outcome in the dexamethasone group as compared with the placebo group. CI denotes confidence interval.

Not adjusted for center because of convergence issues.